Lucevida Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 11-12-2024
- Paid Up Capital ₹ 1.30 M
as on 11-12-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 M
as on 11-12-2024
- Revenue 67.29%
(FY 2017)
- Profit -473.71%
(FY 2017)
- Ebitda -476.00%
(FY 2017)
- Net Worth 217.15%
(FY 2017)
- Total Assets 47.08%
(FY 2017)
About Lucevida Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.30 M.
The company currently has active open charges totaling ₹3.00 M.
Dibakar Paul, Subrata Kundu, Jhoni Roy, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909WB2014PTC203886
- Company No.
203886
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Darjiling, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Lucevida Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dibakar Paul  | Director | 28-Oct-2014 | Current |
| Subrata Kundu | Director | 31-Jan-2015 | Current |
| Jhoni Roy | Director | 22-Apr-2022 | Current |
| Abhijit Kundu | Director | 08-Feb-2020 | Current |
Financial Performance of Lucevida Pharmaceuticals.
Lucevida Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 67.29% increase. The company also saw a substantial fall in profitability, with a 473.71% decrease in profit. The company's net worth Soared by an impressive increase of 217.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lucevida Pharmaceuticals?
In 2017, Lucevida Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.30 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Sep 2020 | State Bank Of India | ₹3.00 M | Open |
How Many Employees Work at Lucevida Pharmaceuticals?
Lucevida Pharmaceuticals has a workforce of 31 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lucevida Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lucevida Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
